Clinical trial
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT07913594 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
- Lead sponsor
- Olivia Newton-John Cancer Research Institute
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- December 31, 2030
- Enrollment
- 25 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
peripheral t-cell lymphoma refractory
Arms
As registered; 1 arm.
-
Zilovertamab vedotin (1.75mg/kg) Q3W + Lenalidomide (15mg p.o. 14 days)
Induction phase:
Zilovertamab vedotin (1.75mg/kg) will be administered using a 30-minute IV infusion on Day 1 of Cycle 1, and then on Day 1 of each 3-week (21-day) cycle, for up to 6 cycles. Capsules of lenalidomide (15mg) will be administered orally (p.o) on planned dosing days (14 days per cycle) for up to 6 cycles.
Participants will have FDG PET/CT scans at the start of the study, prior to induction treatment and following cycle 2 and 6. Response assessments will be undertaken according to Lugano criteria. Participants achieving an objective response will continue onto maintenance phase.
Maintenance phase:
Lenalidomide treatment (15mg p.o, 14 days of a 21 day cycle) for up to 6 additional cycles.
After finishing treatment, participants will attend follow-up visits every 3 months for up to 24 months.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Rate of complete response to up to 6 cycles of combination zilovertamab vedotin and lenalidomide
Rate of complete response to up to 6 cycles of combination zilovertamab vedotin and lenalidomide as determined by first documented disease progression per Lugano response criteria.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
LENALIDOMIDE
- US 8741929; expires March 8, 2028; assignee Celgene (United States)
- US 7465800; expires April 27, 2027; assignee Celgene (United States)
- US 5635517; expires October 4, 2019; assignee Celgene (United States)
Lead sponsor's other trials
Olivia Newton-John Cancer Research Institute, most recent start first.
+8 more trials See the organization page
Similar trials
Same condition (Recurrence) and phase, most recent start first.
+892 more trials See the condition page